Reverdia hires a New Business Development Manager for Europe

Reverdia is the joint venture between Royal DSM and Roquette

Reverdia has appointed Pascal Moritz as the company's Business Development Manager for Europe.

Moritz brings a wealth of experience and a strong industry network to the company. He was previously Business Manager at the bio-based polymers division of Roquette Frères for more than 20 years, in various commercial roles.

Jo Kockelkoren, Reverdia’s Global Commercial Director said: 'We are thrilled to bring such an experienced person into the team. This appointment underlines Reverdia’s long-term commitment to further developing and leading the bio-succinic acid market. We have been producing commercial-scale Biosuccinium in our 10,000 MT capacity plant in Cassano, Italy since 2013. Reverdia has already commercialised, low pH yeast-based succinic acid and also offers access to its patented Biosuccinium technology under licence.'

Reverdia is the joint venture between Royal DSM, the global life sciences and materials sciences company, and Roquette Frères, the global starch and starch-derivatives company. Combining the knowledge and experience of DSM and Roquette, Reverdia produces, sells and licences Biosuccinium.

You may also like

Ingredients

C2 PHARMA expands ophthalmic API portfolio with Naphazoline Hydrochloride launch

C2 PHARMA, the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), proudly announces the launch of its latest API, Naphazoline Hydrochloride
Manufacturing

Quotient Sciences and Vasa Therapeutics announce dosing of first subjects in VS-041 novel heart failure trial

The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of VS-041 in healthy volunteers
Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient
Ingredients

Sigrid Therapeutics' Glucose Stabiliser listed on US e-commerce site, GetHealthy.store

The non-pharmaceutical silica solution can assist patients in managing their blood sugar, while reducing bloating and increasing energy levels
Ingredients

ICROM has acquired HOLODIAG

ICROM srl, an italian API CDMO, has acquired the French-based Contract Research Organization HOLODIAG sas specialized in solid state studies and crystallization services of small molecules
Ingredients

Olon continues its growth with a new acquisition

The acquisition of Huvepharma Italia Srl increases production capacity and expands market presence
Ingredients

Familial chylomicronaemia syndrome: olezarsen

Familial chylomicronaemia syndrome (FCS) is a rare genetic disease that causes extremely high levels of triglycerides. It is the result of the enzyme lipoprotein lipase not working properly, which leaves patients unable to break down chylomicrons effectively
Subscribe now